Patents by Inventor Bharathi Sriram
Bharathi Sriram has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8202516Abstract: The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions.Type: GrantFiled: May 4, 2007Date of Patent: June 19, 2012Assignee: GangaGen, Inc.Inventors: Sriram Padmanabhan, Vivek Daniel Paul, R. Sanjeev Saravanan, Bharathi Sriram
-
Publication number: 20120058211Abstract: The invention provides therapeutic, defined-dose anti-bacterial phage preparations, methods to make such preparations, methods to treat bacterial infections using such preparations and methods to diagnose bacterial infections using such preparations.Type: ApplicationFiled: November 9, 2011Publication date: March 8, 2012Applicant: GangaGen, Inc.Inventors: Jayasheela Manur, Bharathi Sriram, Sriram Padmanabhan
-
Publication number: 20110064699Abstract: The present invention provides methods and compositions to reduce prevalence of plasmids in microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions. Means are provided to reduce the copy numbers of antibiotic resistance genes, and to confer phage binding to cells lacking receptors for those phage.Type: ApplicationFiled: March 10, 2009Publication date: March 17, 2011Applicant: GangaGen, Inc.Inventors: C.B. Appaiah, Jayashella Manur, Bharathi Sriram
-
Publication number: 20100303862Abstract: The present invention features incapacitated whole-cell bacterial immunogenic compositions and methods of their production, which compositions are useful to deliver antigens in a manner resembling the live infectious organism in terms of elicitation of a robust immune response, but with reduced risk or no risk of disease. The compositions of the invention are produced by rendering a bacterium bacteriostatic through expression of a recombinant promoter in the bacterial cell, which promoter can be operably linked to a polynucleotide encoding a recombinant gene product. In one embodiment, where the bacterium is a gram negative host, the recombinant gene product provides for reduced toxicity of LPS. In one embodiment, the gene product is a bacteriophage protein, such as endolysin, holin, or ndd.Type: ApplicationFiled: September 15, 2009Publication date: December 2, 2010Applicant: GANGAGEN, INC.Inventors: Janakiraman Ramachandran, Sriram Padmanabhan, Bharathi Sriram
-
Publication number: 20090324576Abstract: The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions.Type: ApplicationFiled: May 4, 2007Publication date: December 31, 2009Applicant: GangaGen, Inc.Inventors: Sriram Padmanabhan, Vivek Daniel Paul, R. Sanjeev Saravanan, Bharathi Sriram
-
Publication number: 20070020240Abstract: The invention provides therapeutic, defined-dose anti-bacterial phage preparations, methods to make such preparations, methods to treat bacterial infections using such preparations and methods to diagnose bacterial infections using such preparations.Type: ApplicationFiled: October 6, 2004Publication date: January 25, 2007Applicant: GangaGen, Inc.Inventors: M. Jayasheela, Bharathi Sriram, Sriram Padmanabhan
-
Patent number: 7087226Abstract: The present invention features therapeutic bacteriophage deficient in the lysin protein (“Lys minus” phage). Lys minus bacteriophage are incapable of facilitating efficient lysis of the bacterial host since the enzymatic activity of the lysin of the phage is needed for breaking down the peptidoglycan layer of the bacterial cell wall. Lys minus bacteriophage retain activity in invasion of its appropriate bacterial host, destruction of the bacterial genome, and replication, which are sufficient to inhibit bacterial growth and replication. Therefore, the therapeutic Lys minus phage stops the spread of infection by the bacterial pathogen without lysis of the bacterium. This approach is attractive as it also prevents the release of the phage progeny, thus reducing or eliminating the potential for generation of immune responses against the phage. The incapacitated bacterial pathogen is then removed by the normal defense systems such as phagocytes and macrophages.Type: GrantFiled: February 8, 2005Date of Patent: August 8, 2006Assignee: Gangagen, Inc.Inventors: Janakiraman Ramachandran, Sriram Padmanabhan, Bharathi Sriram
-
Publication number: 20050226851Abstract: The present invention features therapeutic bacteriophage deficient in the lysin protein (“Lys minus” phage). Lys minus bacteriophage are incapable of facilitating efficient lysis of the bacterial host since the enzymatic activity of the lysin of the phage is needed for breaking down the peptidoglycan layer of the bacterial cell wall. Lys minus bacteriophage retain activity in invasion of its appropriate bacterial host, destruction of the bacterial genome, and replication, which are sufficient to inhibit bacterial growth and replication. Therefore, the therapeutic Lys minus phage stops the spread of infection by the bacterial pathogen without lysis of the bacterium. This approach is attractive as it also prevents the release of the phage progeny, thus reducing or eliminating the potential for generation of immune responses against the phage. The incapacitated bacterial pathogen is then removed by the normal defense systems such as phagocytes and macrophages.Type: ApplicationFiled: February 8, 2005Publication date: October 13, 2005Inventors: Janakiraman Ramachandran, Sriram Padmanabhan, Bharathi Sriram
-
Patent number: 6913753Abstract: The invention features incapacitated whole cell bacterial immunogenic compositions produced by infecting a bacterium with Lys minus bacteriophage, which are deficient in the lysin protein. Lys minus bacteriophage retain activity in infection of its appropriate bacterial host, destruction of the bacterial genome, and replication, which are sufficient to inhibit bacterial growth and replication. The resulting, Lys minus-infected bacterium is provided in a state of bacteriostasis, and is not capable of replicating further (e.g., is “incapacitated”). The incapacitated bacterium can then be used as to elicit an immune response for prophylactic and/or therapeutic purposes. The invention thus also features incapacitated bacteria formulated appropriately for use in immunogenic compositions for eliciting an immune response, e.g., for production of antibodies in a non-human host or in a whole cell bacterial vaccine.Type: GrantFiled: September 27, 2002Date of Patent: July 5, 2005Assignee: Gangagen, Inc.Inventors: Janakiraman Ramachandran, Sriram Padmanabhan, Bharathi Sriram
-
Publication number: 20050129711Abstract: The present invention features incapacitated whole-cell bacterial immunogenic compositions and methods of their production, which compositions are useful to deliver antigens in a manner resembling the live infectious organism in terms of elicitation of a robust immune response, but with reduced risk or no risk of disease. The compositions of the invention are produced by rendering a bacterium bacteriostatic through expression of a recombinant promoter in the bacterial cell, which promoter can be operably linked to a polynucleotide encoding a recombinant gene product. In one embodiment, where the bacterium is a gram negative host, the recombinant gene product provides for reduced toxicity of LPS. In one embodiment, the gene product is a bacteriophage protein, such as endolysin, holin, or ndd.Type: ApplicationFiled: November 14, 2003Publication date: June 16, 2005Inventors: Janakiraman Ramachandran, Sriram Padmanabhan, Bharathi Sriram
-
Patent number: 6896882Abstract: The present invention features therapeutic bacteriophage deficient in the lysin protein (“Lys minus” phage). Lys minus bacteriophage are incapable of facilitating efficient lysis of the bacterial host since the enzymatic activity of the lysin of the phage is needed for breaking down the peptidoglycan layer of the bacterial cell wall. Lys minus bacteriophage retain activity in invasion of its appropriate bacterial host, destruction of the bacterial genome, and replication, which are sufficient to inhibit bacterial growth and replication. Therefore, the therapeutic Lys minus phage stops the spread of infection by the bacterial pathogen without lysis of the bacterium. This approach is attractive as it also prevents the release of the phage progeny, thus reducing or eliminating the potential for generation of immune responses against the phage. The incapacitated bacterial pathogen is then removed by the normal defense systems such as phagocytes and macrophages.Type: GrantFiled: September 27, 2002Date of Patent: May 24, 2005Assignee: Gangagen, Inc.Inventors: Janakiraman Ramachandran, Sriram Padmanabhan, Bharathi Sriram
-
Publication number: 20040156831Abstract: The present invention features composition and methods for treating a bacterial infection using therapeutic bacteriophage having a modified holin gene. The modified holin inactivates the bacterial host prior to production of bacteriophage, so that the bacteriophage infection is non-productive, e.g., few or no bacteriophage are produced as a result of infection of the bacterial host. Thus, holin-modified bacteriophage invade the bacterial host, and cause inactivation of the bacterial host prior to production of a detectable or significant number of phage. Holin-modified phage inhibit the spread of bacterial infection without production of a significant or detectable number of phage progeny. By avoiding the release of phage progeny, the potential for generation of immune responses against the phage is reduced.Type: ApplicationFiled: November 14, 2003Publication date: August 12, 2004Inventors: Janakiraman Ramachandran, Sriram Padmanabhan, Bharathi Sriram
-
Publication number: 20030152589Abstract: The invention features incapacitated whole cell bacterial immunogenic compositions produced by infecting a bacterium with Lys minus bacteriophage, which are deficient in the lysin protein. Lys minus bacteriophage retain activity in infection of its appropriate bacterial host, destruction of the bacterial genome, and replication, which are sufficient to inhibit bacterial growth and replication. The resulting, Lys minus-infected bacterium is provided in a state of bacteriostasis, and is not capable of replicating further (e.g., is “incapacitated”). The incapacitated bacterium can then be used as to elicit an immune response for prophylactic and/or therapeutic purposes. The invention thus also features incapacitated bacteria formulated appropriately for use in immunogenic compositions for eliciting an immune response, e.g., for production of antibodies in a non-human host or in a whole cell bacterial vaccine.Type: ApplicationFiled: September 27, 2002Publication date: August 14, 2003Inventors: Janakiraman Ramachandran, Sriram Padmanabhan, Bharathi Sriram
-
Publication number: 20030118558Abstract: The present invention features therapeutic bacteriophage deficient in the lysin protein (“Lys minus” phage). Lys minus bacteriophage are incapable of facilitating efficient lysis of the bacterial host since the enzymatic activity of the lysin of the phage is needed for breaking down the peptidoglycan layer of the bacterial cell wall. Lys minus bacteriophage retain activity in invasion of its appropriate bacterial host, destruction of the bacterial genome, and replication, which are sufficient to inhibit bacterial growth and replication. Therefore, the therapeutic Lys minus phage stops the spread of infection by the bacterial pathogen without lysis of the bacterium. This approach is attractive as it also prevents the release of the phage progeny, thus reducing or eliminating the potential for generation of immune responses against the phage. The incapacitated bacterial pathogen is then removed by the normal defense systems such as phagocytes and macrophages.Type: ApplicationFiled: September 27, 2002Publication date: June 26, 2003Inventors: Janakiraman Ramachandran, Sriram Padmanabhan, Bharathi Sriram